Access Insights Conference

Albert Thigpen, co-founder, Talentwise Consulting, explains how the specialty pharmacy sector has evolved over the years.

Albert Thigpen, co-founder, Talentwise Consulting, discusses the valuable buckets pertaining to the PBM space.

Albert Thigpen, co-founder, Talentwise Consulting, explains how to use these tactics in order to anticipate the future US healthcare policy environment.

Albert Thigpen, co-founder, Talentwise Consulting, offers highlights of the drug commercialization panel that he participated in.

Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses key takeaways of the breakout session.

A panel dives into the current and future outlook of healthcare policies.

Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the key takeaways of this year's keynote speech.

Session dives into how healthcare policy implementation impacts stakeholders long-term.

William Sarraille, professor, University of Maryland Francis King Carey School of Law, discusses other standout sessions at this year’s Access Insights conference.

The session dives into the obstacles surrounding data usability, mandate compliance, initial adoption, and limitations in this arena.

William Sarraille, professor, University of Maryland Francis King Carey School of Law, discusses breakout session and the impact of healthcare policies on manufacturing and commercialization.

The conference’s opening keynote sets the scene for 2025 and the years to come.

This year’s conference—taking place in Washington, DC— will prioritize the tackling of business, economic, and healthcare policy obstacles when it comes to decision marking and net revenue optimization.

Blue Fin Group exec speaks on his upcoming feature.

Blue Fin Group executive highlights how leaders can plan for immediate profitable lifecycles and beyond.

SVP and Managing Director for Blue Fin Group offers a synopsis of the conference opener.

Session explains how to use this information to help bolster market intelligence, market access, and affordability strategies.

Conference presentation explores groundbreaking topics impacting the pharma industry.

Director of Berkeley Research Group explains changes to 340B moving forward.

Berkeley Research Group executive speaks about the role of manufacturers in 340B pricing.

Berkeley Research Group Director discusses what to expect at his upcoming session.

Session explores how on-market products have done, and what to expect from new biosimilars.

Conference session discusses the drivers, practical considerations, success factors, and landscape for next-generation pharmacy innovation.

Bill Roth provides insight as to how where chief commercial officers and access leaders can plan for a profitable product lifecycle.